Curisincis A Biotechnology Company Dedicated To Developing And Commercializing Innovative Therapeutics For Cancer Treatmentfounded In 1991 And Re Established In 2000Curis Is Headquartered In Lexingtonmassachusettsthe Company Focuses On Discovering And Developing Drug Candidates For Various Human Cancers Curis S Clinical Pipeline Includes Several Promising Drug Candidatessuch As Emavusertiban Irak4 Kinase Inhibitor In Trials For Acute Myeloid Leukemiafimepinostata Dual Inhibitor For Diffuse Large B Cell Lymphomaand Ca 170 And Ca 327Both Targeting Pd L1 And Tim3A Notable Product Is Erivedgevismodegib An Fda Approved Treatment For Advanced Basal Cell Carcinomadeveloped In Collaboration With Genentech Incand Roche Curis Has Formed Strategic Partnerships To Enhance Its Research And Development Effortsincluding Collaborations With Genentech And Aurigene Discovery Technologieswith A Revenue Of $35 7 Million In 2022 And A Dedicated Teamcuris Is Making Significant Strides In The Biotechnology Sectorparticularly In Oncology
